Hippocampal mammalian target of rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test
- 3 July 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 32 (8) , 922-931
Abstract
Background: Cannabidiol is a non-psychotomimetic compound with antidepressant-like effects. However, the mechanisms and brain regions involved in cannabidiol effects are not yet completely understood. Brain-derived neurotrophic factor/tropomyosin-receptor kinase B/mammalian target of rapamycin (BDNF-TrkB-mTOR) signaling, especially in limbic structures, seems to play a central role in mediating the effects of antidepressant drugs. Aim: Since it is not yet known if BDNF-TrkB-mTOR signaling in the hippocampus is critical to the antidepressant-like effects of cannabidiol, we investigated the effects produced by cannabidiol (10/30/60 nmol/0.2 µL) micro-injection into the hippocampus of mice submitted to the forced swim test and to the open field test. Methods: Independent groups received intra-hippocampal injections of rapamycin (mTOR inhibitor, 0.2 nmol/0.2 µL) or K252 (Trk antagonist, 0.01 nmol/0.2 µL), before the systemic (10 mg/kg) or hippocampal (10 nmol/0.2µL) injection of cannabidiol, and were submitted to the same tests. BDNF levels were analyzed in the hippocampus of animals treated with cannabidiol (10 mg/kg). Results: Systemic cannabidiol administration induced antidepressant-like effects and increased BDNF levels in the dorsal hippocampus. Rapamycin, but not K252a, injection into the dorsal hippocampus prevented the antidepressant-like effect induced by systemic cannabidiol treatment (10 mg/kg). Differently, hippocampal administration of cannabidiol (10 nmol/0.2 µL) reduced immobility time, an effect that was blocked by both rapamycin and K252a local microinjection. Conclusion: Altogether, our data suggest that the hippocampal BDNF-TrkB-mTOR pathway is vital for cannabidiol-induced antidepressant-like effect when the drug is locally administered. However, other brain regions may also be involved in cannabidiol-induced antidepressant effect upon systemic administration.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo
This publication has 52 references indexed in Scilit:
- Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1 (TRPV1) ChannelsNeuroscience & Biobehavioral Reviews, 2014
- The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid systemInternational Journal of Neuropsychopharmacology, 2013
- Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stressProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2013
- Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disordersPhilosophical Transactions of the Royal Society B: Biological Sciences, 2012
- The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticityDevelopmental Neurobiology, 2010
- Panicolytic-like effect of BDNF in the rat dorsal periaqueductal grey matter: the role of 5-HT and GABAInternational Journal of Neuropsychopharmacology, 2010
- Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of ratsPsychopharmacology, 2008
- Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppressionProceedings of the National Academy of Sciences, 2006
- Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamideBritish Journal of Pharmacology, 2001
- A possible alarm substance in the forced swimming testPhysiology & Behavior, 1990